• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

    77.52 -0.52 (-0.67%)
    Official Closing Price Updated: 7:00 PM EDT, Jul 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 335,094
    Open 77.93
    Bid (Size) 76.53 (1)
    Ask (Size) 78.64 (1)
    Prev. Close 78.04
    Today's Range 77.29 - 78.05
    52wk Range 61.60 - 78.08
    Shares Outstanding 166,301,231
    Dividend Yield 1.26%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
    DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why. 
    Via Chartmill
    Dr. Reddy's Labs Stock Sees Improved Technical Strength
    On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
    Via Investor's Business Daily

    Performance

    YTD
    +9.45%
    +9.45%
    1 Month
    +6.81%
    +6.81%
    3 Month
    +5.18%
    +5.18%
    6 Month
    +10.96%
    +10.96%
    1 Year
    +23.97%
    +23.97%

    More News

    Read More
    Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
    Via Benzinga
    Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
    From Aurigene Pharmaceutical Services Ltd.
    Via Business Wire
    Dr Reddy's Laboratories: Q3 Earnings Insights
    Via Benzinga
    Is NYSE:RDY suited for quality investing?
    Via Chartmill
    Should you consider NYSE:RDY for quality investing?
    Via Chartmill
    Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
    Via Investor's Business Daily
    Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
    From Dr. Reddy's Laboratories Ltd.
    Via Business Wire
    Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
    From Alvotech
    Via GlobeNewswire
    RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
    Via InvestorPlace
    Dr. Reddy’s Q4 & Full Year FY24 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
    From Dr. Reddy's Laboratories Ltd.
    Via Business Wire
    Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Dr. Reddy’s Q3 & 9M FY24 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
    From Dr. Reddy's Laboratories Ltd.
    Via Business Wire
    Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
    From Coya Therapeutics, Inc.
    Via Business Wire
    2 overlooked stocks that crushed earnings but traded lower
    Via MarketBeat
    Exposures Product Safety
    Dr. Reddy’s Q2 FY24 Financial Results
    From Dr. Reddy’s Laboratories Ltd.
    Via Business Wire
    Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities.
    Via Chartmill
    Top 5 Health Care Stocks That May Fall Off A Cliff
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.